Turnstone Biologics

Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and potentially cure patients with solid tumors. The company pioneered Selected TIL (tumor-infiltrating lymphocyte) therapy, a next-generation cell therapy approach that selects and expands tumor-reactive T cells for adoptive transfer. Turnstone's programs target challenging solid tumor indications including melanoma, cervical cancer, and other cancers with high unmet need. The company was publicly traded (NASDAQ: TSBX) before its assets were acquired, and its programs were built on the foundational research on TIL therapy developed at the National Cancer Institute.